Cancer patients who develop anemia are often treated with erythropoietin-stimulating agents (ESAs), including darbepoetin alfa (DA) or epoetin alfa (EA). This study compared baseline characteristics, patterns of ESA use, costs, and dosing among cancer patients as observed in a large managed care claims database. METHODS: Medical and pharmacy claims from a U.S. managed care database were used to identify 15,007 unique episodes of care (7238 with DA, 7769 with EA) in cancer patients between January 2004 and 2006. Episodes included all ESA claims with ≤42 day gap between claims, plus a duration of clinical benefit based on the median days between consecutive doses for each product. The dose conversion ratio was calculated as the mean weekly dose of EA to DA. Six sensitivity analyses examined the robustness of findings to study methods. Costs were determined from plan allowed amounts for ESA claims.
PCN35 OUTPATIENT USE OF HEMATOPOIETIC COLONY STIMULATING FACTORS (CSF) AMONG ELDERLY CANCER PATIENTS WITH CHEMOTHERAPY
Shih YCT, Xu Y, Elting LS The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA OBJECTIVES: Recent studies have established aging as a risk factor of chemotherapy-induced neutropenia. Thus, the 2006 ASCO guideline added prophylactic use of CSF in older cancer patients to its recommendations. Our study examined current patterns of CSF use in outpatient settings in this population.
METHODS:
We selected cancer patients with chemotherapy from the [2001] [2002] [2003] [2004] Medicare MarketScan data, a proprietary dataset collecting Medicare and commercial claims for a group of retirees with Medicare supplemental insurance. We defined the index date as the first date of chemotherapy, followed patients for 60 days, and classified high-risk patients as those whose chemotherapy regimens had a greater than 40% risk of neutropenia. We identified outpatient CSF use using HCPCS codes and conducted logistic regression to examine factors associated with CSF use; factors included age, gender, cancer types, risk class, geographic regions, and the index year. A subgroup analysis of the high-risk patients was also performed. RESULTS: We found CSF use in 8. 71% (5455 in 62,647) Baylatry MT, Joly AC, Prugnaud JL, Tilleul P Saint Antoine Hospital, Paris cedex 12, France OBJECTIVES: The payment of costly drugs is not included in the DRG price within the context of the French case-mix based hospital payment system (termed T2A) since 2005/01/01. These drugs will be reimbursed on an additional cost basis after implementation of a "best practices" agreement (good practice reference guidelines drawn up by scientific societies and registration agencies). The objective of this study was to assess the proportion of off-label costly anticancer drug use in terms of reference guidelines in oncology and the impact of their unreimbursement on the hospital activity. METHODS: A 18-month retrospective study (2005/01/01-2006/06/30) was performed in oncology department. 11 costly anticancer drugs were eligible for the additional reimbursement. 8416 adult patient prescriptions (943 patients) including at least one of the eleven studied drugs were analysed. For each prescription, the anticancer drug cost was calculated. The analysis of use was performed by drug: conformity to the official labelling (indication, dose, route of administration) and level of scientific evidence. The off-label anticancer drug use was discussed with prescribers in drug committee. RESULTS: The proportion of off-label costly anticancer drug use is 32% (2693/8416 prescriptions) and represents 29% (€2,020,373/ €6,877,879) of oncology overall drug budget. Among these prescriptions, 43% (1153/2693 prescriptions) were supported by at least one randomized phase III trial and represent 59% (€1,191,068/€2,020,373) of the oncology costly anticancer drug induced cost. CONCLUSION: The reference guidelines should lead towards the good use of these drugs and allow the sick funds to control prescriptions. However, the official labelling of drugs is unable to answer to all clinical situations and cannot be the own references for costly anticancer drug reimbursement. The anticancer drug prescriptions from therapeutic progress (justified off label used) need to be reimbursed to maintain quality of cancer care in French hospitals. University of Pécs, Pécs, Hungary OBJECTIVES: Nationwide organized breast cancer screening programme was launched 2002 in Hungary for women between the age of 45-65 with a 2 years screening interval. The aim of the study is to analyse the within country inequalities of mammography coverage of the organized programme. METHODS: Data derive from the database of the National Health Insurance Fund Administration (OEP) containing routinely collected financial data. The study includes all the women aged 45-64 having either screening or diagnostic mammography before (2000) (2001) and after (2002-2003 and 2004-2005 ) the introduction of organized screening. The regional inequalities are calculated for 19 counties and Budapest as the capital (altogether 20 items). Coverage is defined as the proportion of women resident who have had a mammogram at least once in the previous 2 years. RESULTS: National mammography coverage was 26. 7%, 54,6% and 51,6% in 2000-2001, 2002-2003 and 2004-2005 4 (2004-2005) . CONCLUSION: We found significant within country differences in mammography coverage, however the gap between counties with lowest and highest coverage became smaller after the introduction of organized screening programme. Evidence guiding NSCLC treatment has been derived largely from controlled trials at academic centers. Much less attention has focused on understanding NSCLC treatment by community-based oncologists. We undertook this study to better understand NSCLC treatment patterns and outcomes in community-based practices. METHODS: Ten large communitybased oncology practices in the U.S. were identified. Investigators conducted chart reviews on 417 NSCLC patients treated with chemotherapy between 2001 and 2003 who were deceased at the time of the review. RESULTS: Of the 417 patients (54% male, median age 68 years, mean performance status 1.2) almost 20% had a history of radiation therapy, and 9.6% had a history of surgery. Mean survival was 10.5 months for stage IIIB patients (n = 114) and 7.9 months for stage IV patients (n = 303). In their first line of chemotherapy, 55% of patients received both carboplatin and paclitaxel (18% in combination with radiation therapy). Another 11% received carboplatin with either gemcitabine (6%) or doctaxel (5%). In contrast, monotherapy was more common in second line therapy (docetaxel 22%, gemc-
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